Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 2
2013 3
2014 6
2015 17
2016 19
2017 24
2018 25
2019 22
2020 14
2021 23
2022 33
2023 14
2024 22
2025 16
2026 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

227 results

Results by year

Filters applied: . Clear all
Page 1
Thyroid Cancer: A Review.
Boucai L, Zafereo M, Cabanillas ME. Boucai L, et al. JAMA. 2024 Feb 6;331(5):425-435. doi: 10.1001/jama.2023.26348. JAMA. 2024. PMID: 38319329 Review.
This review summarizes current evidence regarding pathophysiology, diagnosis, and management of early-stage and advanced thyroid cancer. OBSERVATIONS: Papillary thyroid cancer accounts for approximately 84% of all thyroid cancers. Papillary, fol …
This review summarizes current evidence regarding pathophysiology, diagnosis, and management of early-stage and advanced thyroid c …
Thyroid Cancer: Epidemiology, Classification, Risk Factors, Diagnostic and Prognostic Markers, and Current Treatment Strategies.
Forma A, Kłodnicka K, Pająk W, Flieger J, Teresińska B, Januszewski J, Baj J. Forma A, et al. Int J Mol Sci. 2025 May 28;26(11):5173. doi: 10.3390/ijms26115173. Int J Mol Sci. 2025. PMID: 40507982 Free PMC article. Review.
Thyroid cancer (TC) invariably remains the most prevalent endocrine cancer in the world. ...Yet the treatment of advanced or aggressive TC forms has improved recently because of developments in immunotherapy and targeted medicines, including PD-1 inhibitors a …
Thyroid cancer (TC) invariably remains the most prevalent endocrine cancer in the world. ...Yet the treatment of advanc …
Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.
Fleeman N, Houten R, Bagust A, Richardson M, Beale S, Boland A, Dundar Y, Greenhalgh J, Hounsome J, Duarte R, Shenoy A. Fleeman N, et al. Health Technol Assess. 2020 Jan;24(2):1-180. doi: 10.3310/hta24020. Health Technol Assess. 2020. PMID: 31931920 Free PMC article.
RESULTS: Two RCTs were identified: SELECT (Study of [E7080] LEnvatinib in 131I-refractory differentiated Cancer of the Thyroid) and DECISION (StuDy of sorafEnib in loCally advanced or metastatIc patientS with radioactive Iodine-refractory thyrOid …
RESULTS: Two RCTs were identified: SELECT (Study of [E7080] LEnvatinib in 131I-refractory differentiated Cancer of the Thyr …
Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities.
Zhang L, Feng Q, Wang J, Tan Z, Li Q, Ge M. Zhang L, et al. Biochim Biophys Acta Rev Cancer. 2023 Jul;1878(4):188928. doi: 10.1016/j.bbcan.2023.188928. Epub 2023 May 29. Biochim Biophys Acta Rev Cancer. 2023. PMID: 37257629 Free article. Review.
Thyroid cancer (TC) is the most prevalent endocrine malignant tumor. Surgery, chemotherapy, radiotherapy, and radioactive iodine (RAI) therapy are the standard TC treatment modalities. However, recurrence or tumor metastasis remains the main challenge in the managem …
Thyroid cancer (TC) is the most prevalent endocrine malignant tumor. Surgery, chemotherapy, radiotherapy, and radioactive iodi …
Management of follicular thyroid carcinoma.
Yamazaki H, Sugino K, Katoh R, Matsuzu K, Kitagawa W, Nagahama M, Saito A, Ito K. Yamazaki H, et al. Eur Thyroid J. 2024 Oct 16;13(5):e240146. doi: 10.1530/ETJ-24-0146. Print 2024 Oct 1. Eur Thyroid J. 2024. PMID: 39419099 Free PMC article. Review.
Follicular thyroid carcinoma (FTC) is the second most common histological type of thyroid carcinoma. ...Multi-tyrosine kinase inhibitors such as sorafenib and lenvatinib are utilized for treating RAI-refractory FTCs. In addition, given that renin-angio …
Follicular thyroid carcinoma (FTC) is the second most common histological type of thyroid carcinoma. ...Multi-tyrosine kinase …
Use of multikinase inhibitors/lenvatinib in singular thyroid cancer scenarios.
Zafón C, Castelo B. Zafón C, et al. Cancer Med. 2022 Oct;11 Suppl 1(Suppl 1):3-4. doi: 10.1002/cam4.5154. Cancer Med. 2022. PMID: 36202604 Free PMC article.
Thyroid cancer is the most frequent endocrine tumor. In locally advanced or metastatic disease there are only two types of treatment available: radioactive iodine (RAI) while the disease is RAI-sensitive and multikinase inhibitors, lenvatinib and sorafenib …
Thyroid cancer is the most frequent endocrine tumor. In locally advanced or metastatic disease there are only two types of tre …
Lenvatinib rechallenge after failure of lenvatinib and sorafenib in metastatic thyroid cancer.
Yokota T, Hamauchi S, Kawakami T, Fushiki K. Yokota T, et al. Invest New Drugs. 2024 Aug;42(4):361-368. doi: 10.1007/s10637-024-01449-9. Epub 2024 May 29. Invest New Drugs. 2024. PMID: 38809355
The oral multikinase inhibitors sorafenib and lenvatinib are currently available as first-line treatment for patients with unresectable or metastatic thyroid cancer. ...This study aimed to evaluate the safety and efficacy of rechallenged lenvatinib …
The oral multikinase inhibitors sorafenib and lenvatinib are currently available as first-line treatment for patients with unr …
A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine.
Fleeman N, Houten R, Chaplin M, Beale S, Boland A, Dundar Y, Greenhalgh J, Duarte R, Shenoy A. Fleeman N, et al. BMC Cancer. 2019 Dec 12;19(1):1209. doi: 10.1186/s12885-019-6369-7. BMC Cancer. 2019. PMID: 31830943 Free PMC article.
BACKGROUND: Treatment with radioactive iodine is effective for many patients with progressive, locally advanced or metastatic, differentiated thyroid cancer. However, some patients become refractory to treatment. These types of patients are considered to have radioa …
BACKGROUND: Treatment with radioactive iodine is effective for many patients with progressive, locally advanced or metastatic, differentiate …
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.
Brose MS, Robinson B, Sherman SI, Krajewska J, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Hernando J, Faoro L, Banerjee K, Oliver JW, Keam B, Capdevila J. Brose MS, et al. Lancet Oncol. 2021 Aug;22(8):1126-1138. doi: 10.1016/S1470-2045(21)00332-6. Epub 2021 Jul 5. Lancet Oncol. 2021. PMID: 34237250 Clinical Trial.
BACKGROUND: Patients with radioiodine-refractory differentiated thyroid cancer (DTC) previously treated with vascular endothelial growth factor receptor (VEGFR)-targeted therapy have aggressive disease and no available standard of care. ...Patients must have receive …
BACKGROUND: Patients with radioiodine-refractory differentiated thyroid cancer (DTC) previously treated with vascular endothel …
Hand-foot syndrome in sorafenib and lenvatinib treatment for advanced thyroid cancer.
Minaldi E, Cappagli V, Lorusso L, Valerio L, Giani C, Viglione M, Agate L, Molinaro E, Matrone A, Elisei R. Minaldi E, et al. Eur Thyroid J. 2024 Jul 29;13(4):e240009. doi: 10.1530/ETJ-24-0009. Print 2024 Aug 1. Eur Thyroid J. 2024. PMID: 38954633 Free PMC article.
OBJECTIVE: The aim of this study was to assess the clinical impact of hand-foot syndrome (HFS) during treatment with two multikinase inhibitors, sorafenib and lenvatinib, in a large group of patients with advanced thyroid cancer. Moreover, we looked fo …
OBJECTIVE: The aim of this study was to assess the clinical impact of hand-foot syndrome (HFS) during treatment with two multikinase inhibit …
227 results